Increased lucentis dose does not offer additional benefit in retinal venous occlusions

from Wikipedia

Increasing the dose of ranibizumab (lucentis) did not offer any additional benefit in eyes with retinal vein occlusion, neither did laser photocoagulation improve vision or reduce edema significantly more than ranibizumab, according to the results of the RELATE study presented in Macula 2015. 

Portable retinal imaging system approved for sale in European Union and in USA

from d-eyecare.com

Si14 has announced that its D-EYE Portable Retinal Imaging System, a phone-case-sized add-on that turns an iPhone or Android smartphone into a fundus camera capable of taking high-definition video and still images of the eye for health screening and evaluation, is now registered with both the United States Food and Drug Administration and the European CE authority.

EYLEA gets FDA approval for wet AMD, Diabetic macular edema and macular edema following retinal vein occlusion

Regeneron Pharmaceuticals, Inc. has announced that Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection for the treatment of Macular Edema following Retinal Vein Occlusion (RVO), which includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition to the previously-approved indication of Macular Edema following Central Retinal Vein Occlusion (CRVO).